Who we are

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. The company is developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  Prolanta has been granted Orphan Drug status by the FDA for ovarian cancer type, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. In addition to ovarian cancer, there is strong preclinical evidence Prolanta will be effective in breast, prostate and other cancers.

14405 Walters Road, Suite 780, Houston, Texas 77014   
©2011-2014 Oncolix, Inc. All Rights Reserved.